Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 387 articles:
HTML format
Text format



Single Articles


    February 2017
  1. GAHRMANN R, van den Bent M, van der Holt B, Vernhout RM, et al
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  2. HEINZEL A, Muller D, Yekta-Michael SS, Ceccon G, et al
    O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  3. D'ALESSANDRIS QG, Biffoni M, Martini M, Runci D, et al
    The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  4. ABOU-EL-ARDAT K, Seifert M, Becker K, Eisenreich S, et al
    Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  5. MEYRONET D, Esteban-Mader M, Bonnet C, Joly MO, et al
    Characteristics of H3 K27M-mutant gliomas in adults.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  6. TEGLASI V, Reiniger L, Fabian K, Pipek O, et al
    Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


    January 2017
  7. ANTONIOS JP, Soto H, Everson RG, Moughon D, et al
    Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Neuro Oncol. 2017 Jan 23. pii: now287. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. RAMKISSOON SH, Bandopadhayay P, Hwang J, Ramkissoon LA, et al
    Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Neuro Oncol. 2017 Jan 19. pii: now294. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. BERGHOFF AS, Wolpert F, Holland-Letz T, Koller R, et al
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
    Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. BOETTO J, Bielle F, Sanson M, Peyre M, et al
    SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. AYUSO JM, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, et al
    Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events.
    Neuro Oncol. 2017 Jan 6. pii: now230. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. TENG J, Carla da Hora C, Kantar RS, Nakano I, et al
    Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. CHAMBERLAIN MC, Baik CS, Gadi VK, Bhatia S, et al
    Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
    Neuro Oncol. 2017;19:i1-i24.
    PubMed     Text format     Abstract available


  14. BOWMAN RL, Wang Q, Carro A, Verhaak RG, et al
    GlioVis data portal for visualization and analysis of brain tumor expression datasets.
    Neuro Oncol. 2017;19:139-141.
    PubMed     Text format    


    December 2016
  15. WIEDMANN MK, Brunborg C, Di Ieva A, Lindemann K, et al
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
    Neuro Oncol. 2016 Dec 31. pii: now272. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. CICONE F, Galldiks N, Minniti G, Filss CP, et al
    Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.
    Neuro Oncol. 2016 Dec 31. pii: now283. doi: 10.1093.
    PubMed     Text format    


  17. YOUNG RJ, Yang TJ, Hatzoglou V, Ulaner G, et al
    "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
    Neuro Oncol. 2016 Dec 31. pii: now286. doi: 10.1093.
    PubMed     Text format    


  18. MARISETTY AL, Singh SK, Nguyen TN, Coarfa C, et al
    REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
    Neuro Oncol. 2016 Dec 31. pii: now232. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. ROTH P, Valavanis A, Weller M
    Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Neuro Oncol. 2016 Dec 29. pii: now265. doi: 10.1093.
    PubMed     Text format    


  20. KING AA, Seidel K, Di C, Leisenring WM, et al
    Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
    Neuro Oncol. 2016 Dec 29. pii: now242. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. REARDON DA, Lassman AB, van den Bent M, Kumthekar P, et al
    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. TSCHERPEL C, Dunkl V, Ceccon G, Stoffels G, et al
    The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Neuro Oncol. 2016 Dec 29. pii: now243. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. ZHANG AS, Ostrom QT, Kruchko C, Rogers L, et al
    Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Neuro Oncol. 2016 Dec 29. pii: now252. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. ZAMANIPOOR NAJAFABADI AH, Peeters MC, Dirven L, Lobatto DJ, et al
    Impaired health-related quality of life in meningioma patients-a systematic review.
    Neuro Oncol. 2016 Dec 29. pii: now250. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. TOONEN JA, Ma Y, Gutmann DH
    Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
    Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. LIU TT, Achrol AS, Mitchell LA, Rodriguez SA, et al
    Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
    Neuro Oncol. 2016 Dec 22. pii: now270. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  28. LEE J, Hoxha E, Song HR
    A novel NFIA-NFkappaB feed-forward loop contributes to glioblastoma cell survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  29. PENG S, Dhurv H, Armstrong B, Salhia B, et al
    Integrated genomic analysis of survival outliers in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  30. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  31. KLEIN M
    Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma.
    Neuro Oncol. 2016;18:1595-1596.
    PubMed     Text format    


  32. SCHIFF D
    Molecular profiling optimizes the treatment of low-grade glioma.
    Neuro Oncol. 2016;18:1593-1594.
    PubMed     Text format    


    November 2016
  33. LASORELLA A, Sanson M, Iavarone A
    FGFR-TACC gene fusions in human glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  34. SHANKAR GM, Abedalthagafi M, Vaubel RA, Merrill PH, et al
    Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
    Neuro Oncol. 2016 Nov 9. doi: 10.1093.
    PubMed     Text format    


  35. ARMSTRONG FD
    Evidence of cerebral microbleeds and neurocognitive impairment following cranial radiation therapy for pediatric brain tumors: a new opportunity for improved care.
    Neuro Oncol. 2016;18:1470-1471.
    PubMed     Text format    


    October 2016
  36. YAGHI NK, Wei J, Hashimoto Y, Kong LY, et al
    Immune modulatory nanoparticle therapeutics for intracerebral glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  37. MENEI P, Clavreul A, Lemee JM
    Response To "Glioma Resection and Tumor Recurrence: Back To Semmelweis".
    Neuro Oncol. 2016.
    PubMed     Text format    


  38. RATEL D, van der Sanden B, Wion D
    Glioma resection and tumor recurrence: back to Semmelweis.
    Neuro Oncol. 2016.
    PubMed     Text format    


    September 2016
  39. PACKER RJ, Pfister S, Bouffet E, Avery R, et al
    Pediatric low-grade gliomas: implications of the biologic era.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  40. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  41. AVILA EK, Chamberlain M, Schiff D, Reijneveld JC, et al
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  42. WAGNER S, Lanfermann H, Eichner G, Gufler H, et al
    Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  43. PINHEIRO KV, Alves C, Buendia M, Gil MS, et al
    Targeting tyrosine receptor kinase B in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  44. TALASILA KM, Rosland GV, Hagland HR, Eskilsson E, et al
    The angiogenic switch leads to a metabolic shift in human glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  45. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  46. KEBIR S, Rauschenbach L, Galldiks N, Schlaak M, et al
    Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  47. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016 Sep 2. doi: 10.1093.
    PubMed     Text format    


  48. BERENDSEN S, Snijders TJ, Robe PA
    Response to: "Prognostic relevance of epilepsy at presentation in lower-grade gliomas".
    Neuro Oncol. 2016;18:1327-8.
    PubMed     Text format    


  49. WATTS C, Langen KJ
    PET imaging in glioma: is it time for mainstream practice?
    Neuro Oncol. 2016;18:1193-4.
    PubMed     Text format    


    August 2016
  50. ELLINGSON BM, Harris RJ, Woodworth DC, Leu K, et al
    Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  51. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  52. NELSON SJ, Kadambi AK, Park I, Li Y, et al
    Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  53. GOMEZ-ROMAN N, Stevenson K, Gilmour L, Hamilton G, et al
    A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  54. WEFEL JS, Noll KR, Rao G, Cahill DP, et al
    Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  55. ROSENBERG S, Verreault M, Schmitt C, Guegan J, et al
    Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  56. KIM EH, Lee JH, Oh Y, Koh I, et al
    Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  57. WAHL M, Phillips JJ, Molinaro AM, Lin Y, et al
    Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  58. YANG R, Sarkar S, Korchinski DJ, Wu Y, et al
    MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  59. MCTYRE ER, Johnson AG, Ruiz J, Isom S, et al
    Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  60. NGUYEN HN, Lie A, Li T, Chowdhury R, et al
    Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  61. RIGGS L, Piscione J, Laughlin S, Cunningham T, et al
    Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  62. RODDY E, Sear K, Felton E, Tamrazi B, et al
    Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  63. KANN BH, Lester-Coll NH, Park HS, Yeboa DN, et al
    Adjuvant chemotherapy and overall survival in adult medulloblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  64. BERGHOFF AS, Preusser M
    In search of a target: PD-1 and PD-L1 profiling across glioma types.
    Neuro Oncol. 2016.
    PubMed     Text format    


  65. VERMEULEN JF, van Hecke W, Jansen MK, Spliet WG, et al
    No evidence for human cytomegalovirus infection in pediatric medulloblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  66. WICK W, Chinot OL, Bendszus M, Mason W, et al
    Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  67. HU LS, Ning S, Eschbacher JM, Baxter LC, et al
    Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  68. PATEL P, Baradaran H, Delgado D, Askin G, et al
    MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  69. ARVOLD ND, Lee EQ, Mehta MP, Margolin K, et al
    Updates in the management of brain metastases.
    Neuro Oncol. 2016;18:1043-65.
    PubMed     Text format     Abstract available


    July 2016
  70. LI S, Zeng A, Hu Q, Yan W, et al
    miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  71. CECCON G, Lohmann P, Stoffels G, Judov N, et al
    Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  72. ZIEGLER J, Pody R, Coutinho de Souza P, Evans B, et al
    ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  73. LEHMAN NL, Hattab EM, Mobley BC, Usubalieva A, et al
    Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  74. JAFARI-KHOUZANI K, Loebel F, Bogner W, Rapalino O, et al
    Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  75. DUNET V, Prior JO
    Response to: Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1029-30.
    PubMed     Text format    


  76. HUANG X, Bai H, Zhou H, Tang H, et al
    Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1028.
    PubMed     Text format    


  77. LASSALETTA A, Ramaswamy V
    Medulloblastoma in adults: they're not just big kids.
    Neuro Oncol. 2016;18:895-7.
    PubMed     Text format    


  78. BARONE TA, Burkhart CA, Safina A, Haderski G, et al
    Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  79. GOFFART N, Lombard A, Lallemand F, Kroonen J, et al
    CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  80. HASHIZUME R, Zhang A, Mueller S, Prados MD, et al
    Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  81. WICK W, Roth P, Hartmann C, Hau P, et al
    Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  82. ZHOU H, Huang X, Bai HX, Tan X, et al
    Prognostic relevance of epilepsy at presentation in lower-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


    June 2016
  83. LIN H, Patel S, Affleck VS, Wilson I, et al
    Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  84. ZHANG B, Chang K, Ramkissoon S, Tanguturi S, et al
    Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  85. BURTH S, Kickingereder P, Eidel O, Tichy D, et al
    Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  86. OKOLIE O, Bago JR, Schmid RS, Irvin DM, et al
    Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  87. VANNINI E, Olimpico F, Middei S, Ammassari-Teule M, et al
    Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  88. ARMSTRONG TS, Shade MY, Breton G, Gilbert MR, et al
    Sleep-wake disturbance in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  89. MANGANI D, Weller M, Seyed Sadr E, Willscher E, et al
    Limited role for transforming growth factor-beta pathway activation-mediated escape from VEGF inhibition in murine glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  90. ESKILSSON E, Rosland GV, Talasila KM, Knappskog S, et al
    EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  91. JONES C, Karajannis MA, Jones DT, Kieran MW, et al
    Pediatric high-grade glioma: biologically and clinically in need of new thinking.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  92. SCHIFF D
    PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.
    Neuro Oncol. 2016;18:755-6.
    PubMed     Text format    


    May 2016
  93. ESKILSSON E, Verhaak RG
    Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities.
    Neuro Oncol. 2016.
    PubMed     Text format    


  94. FOUNTAIN DM, Allen D, Joannides AJ, Nandi D, et al
    Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  95. GUHASARKAR D, Su Q, Gao G, Sena-Esteves M, et al
    Systemic AAV9-IFNbeta gene delivery treats highly invasive glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  96. LEBLANC AK, Mazcko C, Brown DE, Koehler JW, et al
    Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  97. BERNARD-ARNOUX F, Lamure M, Ducray F, Aulagner G, et al
    The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  98. YAGIZ K, Huang TT, Lopez Espinoza F, Mendoza D, et al
    Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  99. NAGASHIMA H, Tanaka K, Sasayama T, Irino Y, et al
    Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  100. CHANG K, Zhang B, Guo X, Zong M, et al
    Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  101. DE FEYTER HM, Behar KL, Rao JU, Madden-Hennessey K, et al
    A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  102. ZADEH G, Karimi S, Aldape KD
    PIK3CA mutations in meningioma.
    Neuro Oncol. 2016;18:603-4.
    PubMed     Text format    


    April 2016
  103. LAKS DR, Crisman TJ, Shih MY, Mottahedeh J, et al
    Large-scale assessment of the gliomasphere model system.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  104. ZHANG X, Rao A, Sette P, Deibert C, et al
    IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  105. LEDUR PF, Liu C, He H, Harris AR, et al
    Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  106. ZHAO F, Ohgaki H, Xu L, Giangaspero F, et al
    Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  107. MCDONALD CR, Delfanti RL, Krishnan AP, Leyden KM, et al
    Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  108. ALBERT NL, Weller M, Suchorska B, Galldiks N, et al
    Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  109. SEYSTAHL K, Stoecklein V, Schuller U, Rushing E, et al
    Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  110. CORREA DD, Satagopan J, Cheung K, Arora AK, et al
    COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  111. GRANT R, Brown PD
    Fatigue randomized controlled trials-how tired is "too tired" in patients undergoing glioma treatment?
    Neuro Oncol. 2016.
    PubMed     Text format    


  112. PATIL SS, Gokulnath P, Bashir M, Shwetha SD, et al
    Insulin-like growth factor binding protein-2 regulates beta-catenin signaling pathway in glioma cells and together contributes to poor patient prognosis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  113. LEE HJ, Hanibuchi M, Kim SJ, Yu H, et al
    Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
    Neuro Oncol. 2016;18:486-96.
    PubMed     Text format     Abstract available


  114. OSSWALD M, Solecki G, Wick W, Winkler F, et al
    A malignant cellular network in gliomas: potential clinical implications.
    Neuro Oncol. 2016;18:479-85.
    PubMed     Text format     Abstract available


    March 2016
  115. COOK PJ, Thomas R, Kingsley PJ, Shimizu F, et al
    Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  116. LULLA RR, Goldman S, Yamada T, Beattie CW, et al
    Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  117. SZABO E, Schneider H, Seystahl K, Rushing EJ, et al
    Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  118. CHINOT OL, Nishikawa R, Mason W, Henriksson R, et al
    Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  119. YUE X, Cao D, Lan F, Pan Q, et al
    MiR-301a is activated by the Wnt/beta-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  120. JAKACKI RI, Cohen KJ, Buxton A, Krailo MD, et al
    Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  121. GIELEN PR, Schulte BM, Kers-Rebel ED, Verrijp K, et al
    Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  122. CORDOVA JS, Shu HG, Liang Z, Gurbani SS, et al
    Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  123. POLLACK IF, Jakacki RI, Butterfield LH, Hamilton RL, et al
    Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomasdagger.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  124. PIAO Y, Park SY, Henry V, Smith BD, et al
    Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  125. PISKLAKOVA A, McKenzie B, Zemp F, Lun X, et al
    M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  126. YANG P, Cai J, Yan W, Zhang W, et al
    Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  127. XIPELL E, Aragon T, Martinez-Velez N, Vera B, et al
    Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  128. OSTERBERG N, Ferrara N, Vacher J, Gaedicke S, et al
    Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  129. NIGIM F, Esaki SI, Hood M, Lelic N, et al
    A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  130. BRANDES AA, Finocchiaro G, Zagonel V, Reni M, et al
    AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  131. PUROW B
    For glioma, a sweet side to diabetes.
    Neuro Oncol. 2016;18:306-7.
    PubMed     Text format    


  132. HELFER JL, Wen PY, Blakeley J, Gilbert MR, et al
    Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
    Neuro Oncol. 2016;18 Suppl 2:ii26-ii36.
    PubMed     Text format     Abstract available


  133. BLAKELEY JO, Coons SJ, Corboy JR, Leidy NK, et al
    Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
    Neuro Oncol. 2016;18 Suppl 2:ii13-ii20.
    PubMed     Text format     Abstract available


  134. ARMSTRONG TS, Bishof AM, Brown PD, Klein M, et al
    Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
    Neuro Oncol. 2016;18 Suppl 2:ii1-ii12.
    PubMed     Text format     Abstract available


  135. BALLESTER LY, Olar A, Roy-Chowdhuri S
    Next-generation sequencing of central nervous systems tumors: the future of personalized patient management.
    Neuro Oncol. 2016;18:308-10.
    PubMed     Text format    


    February 2016
  136. KATHAGEN-BUHMANN A, Schulte A, Weller J, Holz M, et al
    Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  137. SHOJI T, Saito R, Chonan M, Shibahara I, et al
    Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  138. JALBERT LE, Neill E, Phillips JJ, Lupo JM, et al
    Magnetic resonance analysis of malignant transformation in recurrent glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  139. STELLA GM, Senetta R, Inghilleri S, Verdun di Cantogno L, et al
    MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.
    Neuro Oncol. 2016.
    PubMed     Text format    


  140. BRANDES AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, et al
    A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  141. LEE EQ, Muzikansky A, Drappatz J, Kesari S, et al
    A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  142. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  143. VOGELBAUM MA
    The benefit of surgical resection in recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format    


  144. SOMMERAUER M, Burkhardt JK, Frontzek K, Rushing E, et al
    68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  145. WHEELER LA, Manzanera AG, Bell SD, Cavaliere R, et al
    Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  146. FRANCESCHI S, Lessi F, Aretini P, Mazzanti CM, et al
    Molecular portrait of a rare case of metastatic glioblastoma: somatic and germline mutations using whole-exome sequencing.
    Neuro Oncol. 2016;18:298-300.
    PubMed     Text format    


  147. KESSLER T
    Predicting glioblastoma response to bevacizumab through marker profiling?
    Neuro Oncol. 2016;18:149-50.
    PubMed     Text format    


  148. ALEXANDER BM
    Radiation de-intensification for patients with glioblastoma and poor prognostic features-how much do we really know?
    Neuro Oncol. 2016;18:147-8.
    PubMed     Text format    


  149. BAUMGARTEN P, Blank AE, Franz K, Hattingen E, et al
    Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Neuro Oncol. 2016;18:173-83.
    PubMed     Text format     Abstract available


  150. RUDA R, Bosa C, Magistrello M, Franchino F, et al
    Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Neuro Oncol. 2016;18:261-8.
    PubMed     Text format     Abstract available


    January 2016
  151. KERBEL RS
    Exploiting drug repositioning and the brain microenvironment to treat brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  152. SCHMID RS, Simon JM, Vitucci M, McNeill RS, et al
    Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  153. ABEDALTHAGAFI M, Bi WL, Aizer AA, Merrill PH, et al
    Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  154. SUCHORSKA B, Weller M, Tabatabai G, Senft C, et al
    Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  155. ALKINS R, Burgess A, Kerbel R, Wels WS, et al
    Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  156. SARAN F, Chinot OL, Henriksson R, Mason W, et al
    Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  157. KIM MM, Parmar H, Cao Y, Knox SJ, et al
    Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  158. THORNE AH, Zanca C, Furnari F
    Epidermal growth factor receptor targeting and challenges in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  159. SANCHEZ-OSUNA M, Martinez-Escardo L, Granados-Colomina C, Martinez-Soler F, et al
    An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  160. SOFFIETTI R, Ruda R, Trakul N, Chang EL, et al
    Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?
    Neuro Oncol. 2016;18:12-5.
    PubMed     Text format    


  161. OSTROM QT, Gittleman H, de Blank PM, Finlay JL, et al
    American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
    Neuro Oncol. 2016;18 Suppl 1:i1-i50.
    PubMed     Text format    


  162. SCHIFF D
    Quantifying the burden of primary central nervous system malignancy.
    Neuro Oncol. 2016;18:5-6.
    PubMed     Text format    


  163. ROUSE C, Gittleman H, Ostrom QT, Kruchko C, et al
    Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.
    Neuro Oncol. 2016;18:70-7.
    PubMed     Text format     Abstract available


  164. LEE JK, Chang N, Yoon Y, Yang H, et al
    USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
    Neuro Oncol. 2016;18:37-47.
    PubMed     Text format     Abstract available


    December 2015
  165. DE LA FUENTE MI, Young RJ, Rubel J, Rosenblum M, et al
    Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  166. HATZOGLOU V, Yang TJ, Omuro A, Gavrilovic I, et al
    A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  167. EATON BR, Esiashvili N, Kim S, Patterson B, et al
    Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  168. WIRSCHING HG, Morel C, Gmur C, Neidert MC, et al
    Predicting outcome of epilepsy after meningioma resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  169. HOVER LD, Owens P, Munden AL, Wang J, et al
    Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  170. XU Z, Zeng X, Xu J, Xu D, et al
    Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  171. DI K, Lloyd GK, Abraham V, MacLaren A, et al
    Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  172. WEI J, Nduom EK, Kong LY, Hashimoto Y, et al
    MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  173. MOLINARO AM, Wrensch MR, Jenkins RB, Eckel-Passow JE, et al
    Statistical considerations on prognostic models for glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  174. HWANG WL, Marciscano AE, Niemierko A, Kim DW, et al
    Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  175. XUAN F, Huang M, Liu W, Ding H, et al
    Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  176. DUBINSKI D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, et al
    CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  177. ROELCKE U, Wyss MT, Nowosielski M, Ruda R, et al
    Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  178. STAFFORD JH, Hirai T, Deng L, Chernikova SB, et al
    Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  179. ZHANG M, Gulotta B, Thomas A, Kaley T, et al
    Large-volume low lesion predicts poor survival in bevacizumab-treated glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  180. CAHILL KE, Morshed RA, Yamini B
    Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  181. ARMSTRONG TS, Grant R, Gilbert MR, Lee JW, et al
    Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  182. A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children-"HeadSmart: Be Brain Tumour Aware".
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  183. NDUOM EK, Weller M, Heimberger AB
    Immunosuppressive mechanisms in glioblastoma.
    Neuro Oncol. 2015;17 Suppl 7:vii9-vii14.
    PubMed     Text format     Abstract available


    October 2015
  184. LIU X, Madhankumar AB, Miller PA, Duck KA, et al
    MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  185. TAKANO K, Kinoshita M, Takagaki M, Sakai M, et al
    Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  186. ROGERS CL, Perry A, Pugh S, Vogelbaum MA, et al
    Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  187. POUSSAINT TY, Vajapeyam S, Ricci KI, Panigrahy A, et al
    Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  188. JASSAM SA, Maherally Z, Smith JR, Ashkan K, et al
    TNF-alpha enhancement of CD62E mediates adhesion of non-small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  189. WICK W, Platten M, Wick A, Hertenstein A, et al
    Current status and future directions of anti-angiogenic therapy for gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  190. VELDHUIJZEN VAN ZANTEN SE, van Meerwijk CL, Jansen MH, Twisk JW, et al
    Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  191. BUTOWSKI N, Colman H, De Groot JF, Omuro AM, et al
    Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  192. VAN DER VOS KE, Abels ER, Zhang X, Lai C, et al
    Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  193. NOLL KR, Wefel JS
    Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".
    Neuro Oncol. 2015;17:1421-2.
    PubMed     Text format    


  194. KANE JR
    From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function.
    Neuro Oncol. 2015;17:1420-1.
    PubMed     Text format    


  195. MANSOURI S, Zadeh G
    Neddylation in glioblastomas.
    Neuro Oncol. 2015;17:1305-6.
    PubMed     Text format    


    September 2015
  196. WALBERT T, Pace A
    End-of-life care in patients with primary malignant brain tumors: early is better.
    Neuro Oncol. 2015.
    PubMed     Text format    


  197. JONES KA, Gilder AS, Lam MS, Du N, et al
    Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  198. BERENDSEN S, Varkila M, Kroonen J, Seute T, et al
    Prognostic relevance of epilepsy at presentation in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  199. HOU L, Jiang J, Liu B, Han W, et al
    Smoking and adult glioma: a population-based case-control study in China.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  200. COCKLE JV, Rajani K, Zaidi S, Kottke T, et al
    Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  201. WANG K, Wang Y, Fan X, Wang J, et al
    Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  202. MORANA G, Piccardo A, Puntoni M, Nozza P, et al
    Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  203. HABETS EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, et al
    Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  204. HELLWINKEL JE, Redzic JS, Harland TA, Gunaydin D, et al
    Glioma-derived extracellular vesicles selectively suppress immune responses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  205. HEGI ME, Stupp R
    Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?
    Neuro Oncol. 2015.
    PubMed     Text format    


  206. ALVARADO AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, et al
    Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  207. SHIROISHI MS, Boxerman JL, Pope WB
    Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  208. FILBIN MG, Segal RA
    How neuronal activity regulates glioma cell proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format    


  209. OBEROI RK, Parrish KE, Sio TT, Mittapalli RK, et al
    Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  210. KOCAKAYA S, Beier CP, Beier D
    Chemotherapy increases long-term survival in patients with adult medulloblastoma-a literature-based meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  211. FURTNER J, Schopf V, Seystahl K, Le Rhun E, et al
    Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  212. DUBBINK HJ, Atmodimedjo PN, Kros JM, French PJ, et al
    Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  213. BERTOLINI F, Pecchi A, Stefani A, Fontana A, et al
    Everolimus effectively blocks pulmonary metastases from meningioma.
    Neuro Oncol. 2015;17:1301-2.
    PubMed     Text format    


  214. SUL J, Krainak DM
    Brain tumor clinical trials imaging: a (well-standardized) picture is worth a thousand words.
    Neuro Oncol. 2015;17:1179-80.
    PubMed     Text format    


  215. EVERSON RG, Antonios JP, Lisiero DN, Soto H, et al
    Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  216. NDUOM EK, Wei J, Yaghi NK, Huang N, et al
    PD-L1 expression and prognostic impact in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  217. AIZER AA, Abedalthagafi M, Linda Bi W, Horvath MC, et al
    A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  218. XIA S, Lal B, Tung B, Wang S, et al
    Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  219. ARMSTRONG TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, et al
    The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  220. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format    


  221. DIAMOND EL, Russell D, Kryza-Lacombe M, Bowles KH, et al
    Rates and risks for late referral to hospice in patients with primary malignant brain tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  222. ZHU Y, Zhao K, Prinz A, Keyvani K, et al
    Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  223. BLUML S, Margol AS, Sposto R, Kennedy RJ, et al
    Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  224. ELLINGSON BM, Bendszus M, Boxerman J, Barboriak D, et al
    Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  225. DAVIS B, Shen Y, Poon CC, Luchman HA, et al
    Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  226. TOGAO O, Hiwatashi A, Yamashita K, Kikuchi K, et al
    Differentiation of high-grade and low-grade diffuse gliomas by intravoxel incoherent motion MR imaging.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  227. DUNET V, Pomoni A, Hottinger A, Nicod-Lalonde M, et al
    Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  228. RINGEL F, Pape H, Sabel M, Krex D, et al
    Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  229. TABOURET E, Boudouresque F, Farina P, Barrie M, et al
    MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.
    Neuro Oncol. 2015;17:1174-6.
    PubMed     Text format    


  230. NOWAK J, Seidel C, Pietsch T, Alkonyi B, et al
    Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified.
    Neuro Oncol. 2015;17:1157-65.
    PubMed     Text format     Abstract available


  231. POPE WB
    Predictive imaging marker of bevacizumab efficacy: perfusion MRI.
    Neuro Oncol. 2015;17:1046-7.
    PubMed     Text format    


    July 2015
  232. LUPO JM, Molinaro AM, Essock-Burns E, Butowski N, et al
    The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with gliomadagger.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  233. WALKER PR, Migliorini D
    The CD40/CD40L axis in glioma progression and therapy.
    Neuro Oncol. 2015.
    PubMed     Text format    


  234. LEMEE JM, Clavreul A, Menei P
    Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  235. WANGARYATTAWANICH P, Hatami M, Wang J, Thomas G, et al
    Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  236. PALLUD J, Audureau E, Noel G, Corns R, et al
    Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  237. FRIEDMAN GK, Moore BP, Nan L, Kelly VM, et al
    Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  238. MACYSZYN L, Akbari H, Pisapia JM, Da X, et al
    Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  239. WAITKUS MS, Diplas BH, Yan H
    Isocitrate dehydrogenase mutations in gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  240. HARSHYNE LA, Nasca BJ, Kenyon LC, Andrews DW, et al
    Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  241. OUYANG Q, Chen G, Zhou J, Li L, et al
    Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  242. AGNIHOTRI S, Zadeh G
    Metabolic reprogramming in glioblastoma: The influence of cancer metabolism on epigenetics and unanswered questions.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  243. BADVE C, Sloan AE
    Modeling the growth dynamics of glioblastoma using magnetic resonance imaging.
    Neuro Oncol. 2015.
    PubMed     Text format    


  244. COBBS C
    Reply to: Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1040.
    PubMed     Text format    


  245. MICHAELIS M, Mittelbronn M, Cinatl J Jr
    Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1039.
    PubMed     Text format    


  246. MEHTA MP
    The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients.
    Neuro Oncol. 2015;17:919-23.
    PubMed     Text format    


  247. SAHGAL A
    Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?
    Neuro Oncol. 2015;17:916-8.
    PubMed     Text format    


  248. WEN PY
    Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases.
    Neuro Oncol. 2015;17:915.
    PubMed     Text format    


  249. GUNN ME, Malila N, Lahdesmaki T, Arola M, et al
    Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  250. GONG Y, Ma Y, Sinyuk M, Loganathan S, et al
    Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  251. MASON WP
    Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  252. KREHER S, Johrens K, Strehlow F, Martus P, et al
    Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
    Neuro Oncol. 2015;17:1016-21.
    PubMed     Text format     Abstract available


    June 2015
  253. FIELD KM, Simes J, Nowak AK, Cher L, et al
    Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  254. GALLDIKS N, Langen KJ, Pope WB
    From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  255. ABHINAV K, Yeh FC, Mansouri A, Zadeh G, et al
    High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  256. HARRIS RJ, Cloughesy TF, Liau LM, Prins RM, et al
    pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  257. ACQUAYE AA, Lin L, Vera-Bolanos E, Gilbert MR, et al
    Hope and mood changes throughout the primary brain tumor illness trajectory.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  258. FEICHTINGER RG, Weis S, Mayr JA, Zimmermann FA, et al
    Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  259. SELIGER C, Ricci C, Meier CR, Bodmer M, et al
    Diabetes, use of antidiabetic drugs, and the risk of glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  260. BOSNYAK E, Kamson DO, Guastella AR, Varadarajan K, et al
    Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  261. BADHIWALA JH, Almenawer SA
    Extent of surgical resection of high-grade glioma among the elderly.
    Neuro Oncol. 2015;17:903-4.
    PubMed     Text format    


    May 2015
  262. WEN PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, et al
    Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  263. WALSH KM, Wiencke JK, Lachance DH, Wiemels JL, et al
    Telomere maintenance and the etiology of adult glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  264. PATEL KR, Lawson DH, Kudchadkar RR, Carthon BC, et al
    Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  265. ZHOU Y, Wu S, Liang C, Lin Y, et al
    Transcriptional upregulation of microtubule-associated protein 2 is involved in the protein kinase A-induced decrease in the invasiveness of glioma cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  266. GALLDIKS N, Stoffels G, Filss C, Rapp M, et al
    The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  267. CHONAN M, Saito R, Shoji T, Shibahara I, et al
    CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  268. GERSTNER ER, Ye X, Duda DG, Levine MA, et al
    A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  269. KSHETTRY VR, Ostrom QT, Kruchko C, Al-Mefty O, et al
    Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  270. NICLOU SP
    Gauging heterogeneity in primary versus recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  271. BECKER CM, Oberoi RK, McFarren SJ, Muldoon DM, et al
    Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  272. LIM M
    Immunotherapy for glioblastoma: are we finally getting closer?
    Neuro Oncol. 2015.
    PubMed     Text format    


  273. SCHIFF D, Sarkaria J
    Dasatinib in recurrent glioblastoma: failure as a teacher.
    Neuro Oncol. 2015.
    PubMed     Text format    


  274. VLAHOVIC G, Fecci PE, Reardon D, Sampson JH, et al
    Programmed death-ligand 1(PD-L1) as an immunotherapy target in patients with glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  275. ALEXANDER BM, Trippa L
    Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma.
    Neuro Oncol. 2015;17:765-6.
    PubMed     Text format    


  276. PUHALLA S, Elmquist W, Freyer D, Kleinberg L, et al
    Unsanctifying the sanctuary: challenges and opportunities with brain metastases.
    Neuro Oncol. 2015;17:639-651.
    PubMed     Text format     Abstract available


  277. PRADOS MD, Byron SA, Tran NL, Phillips JJ, et al
    Toward precision medicine in glioblastoma: the promise and the challenges.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  278. ACHARYA S, DeWees T, Shinohara ET, Perkins SM, et al
    Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas.
    Neuro Oncol. 2015;17:741-6.
    PubMed     Text format     Abstract available


  279. MUNCH TN, Gortz S, Wohlfahrt J, Melbye M, et al
    The long-term risk of malignant astrocytic tumors after structural brain injury--a nationwide cohort study.
    Neuro Oncol. 2015;17:718-24.
    PubMed     Text format     Abstract available


  280. LEE J, Dang X, Borboa A, Coimbra R, et al
    Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation.
    Neuro Oncol. 2015;17:685-96.
    PubMed     Text format     Abstract available


  281. HORNQUIST L, Rickardsson J, Lannering B, Gustafsson G, et al
    Altered self-perception in adult survivors treated for a CNS tumor in childhood or adolescence: population-based outcomes compared with the general population.
    Neuro Oncol. 2015;17:733-40.
    PubMed     Text format     Abstract available


    April 2015
  282. CAMPANELLA F, Fabbro F, Ius T, Shallice T, et al
    Acute effects of surgery on emotion and personality of brain tumor patients: surgery impact, histological aspects, and recovery.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  283. WANG TJ, Saad S, Qureshi YH, Jani A, et al
    Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  284. RAPKINS RW, Wang F, Nguyen HN, Cloughesy TF, et al
    The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  285. HUA W, Li C, Yang Z, Li L, et al
    Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  286. ARMSTRONG TS, Ying Y, Wu J, Acquaye AA, et al
    The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  287. SCHATLO B, Fandino J, Smoll NR, Wetzel O, et al
    Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  288. CHINTAGUMPALA M, Eckel SP, Krailo M, Morris M, et al
    A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study dagger.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  289. STERKENBURG AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, et al
    Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  290. OSTROM QT, Bauchet L, Davis FG, Deltour I, et al
    Response to "The epidemiology of glioma in adults: a 'state of the science' review".
    Neuro Oncol. 2015;17:624-6.
    PubMed     Text format    


  291. HUGHES MK
    Sexual dysfunction and brain tumors: why address it?
    Neuro Oncol. 2015;17:483-4.
    PubMed     Text format    


  292. AVULA S, Kumar R, Pizer B, Pettorini B, et al
    Diffusion abnormalities on intraoperative magnetic resonance imaging as an early predictor for the risk of posterior fossa syndrome.
    Neuro Oncol. 2015;17:614-22.
    PubMed     Text format     Abstract available


  293. CHAKRAVADHANULA M, Hampton CN, Chodavadia P, Ozols V, et al
    Wnt pathway in atypical teratoid rhabdoid tumors.
    Neuro Oncol. 2015;17:526-35.
    PubMed     Text format     Abstract available


  294. GAO Y, Whitaker-Dowling P, Barmada MA, Basse PH, et al
    Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.
    Neuro Oncol. 2015;17:536-44.
    PubMed     Text format     Abstract available


    March 2015
  295. BERGTHOLD G, Bandopadhayay P, Hoshida Y, Ramkissoon S, et al
    Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  296. DONG F, Eibach M, Bartsch JW, Dolga AM, et al
    The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  297. OLAR A
    Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  298. KOEKKOEK JA, Kerkhof M, Dirven L, Heimans JJ, et al
    Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  299. SINGH MM, Johnson B, Venkatarayan A, Flores ER, et al
    Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  300. OLSEN TK, Panagopoulos I, Meling TR, Micci F, et al
    Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  301. SUNDSTROM T, Espedal H, Harter PN, Fasmer KE, et al
    Melanoma brain metastasis is independent of lactate dehydrogenase A expression.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  302. NABORS LB, Fink KL, Mikkelsen T, Grujicic D, et al
    Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  303. STENSJOEN AL, Solheim O, Kvistad KA, Haberg AK, et al
    Growth dynamics of untreated glioblastomas in vivo.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  304. ZOU Y, Bai HX, Wang Z, Yang L, et al
    Biopsy versus resection in the management of high-grade gliomas in the elderly.
    Neuro Oncol. 2015.
    PubMed     Text format    


  305. LASSMAN AB, Pugh SL, Gilbert MR, Aldape KD, et al
    Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  306. PLATTEN M, Wick W
    Tregs in gliomas - the jury is still out.
    Neuro Oncol. 2015.
    PubMed     Text format    


  307. KICKINGEREDER P, Wiestler B, Burth S, Wick A, et al
    Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  308. RAMKISSOON SH, Bi WL, Schumacher SE, Ramkissoon LA, et al
    Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  309. ERSON-OMAY EZ, Caglayan AO, Schultz N, Weinhold N, et al
    Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  310. LLOYD RE, Keatley K, Littlewood DT, Meunier B, et al
    Identification and functional prediction of mitochondrial complex III and IV mutations associated with glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  311. WAIT SD, Prabhu RS, Burri SH, Atkins TG, et al
    Polymeric drug delivery for the treatment of glioblastoma.
    Neuro Oncol. 2015;17.
    PubMed     Text format     Abstract available


  312. VOGELBAUM MA, Aghi MK
    Convection-enhanced delivery for the treatment of glioblastoma.
    Neuro Oncol. 2015;17.
    PubMed     Text format     Abstract available


  313. KANE JR, Miska J, Young JS, Kanojia D, et al
    Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.
    Neuro Oncol. 2015;17.
    PubMed     Text format     Abstract available


  314. KALKANIS SN
    Setting the stage: local delivery of cytoreductive agents for the treatment of glioblastoma.
    Neuro Oncol. 2015;17.
    PubMed     Text format    


  315. ZADEH G, Khan OH, Vogelbaum M, Schiff D, et al
    Much debated controversies of diffuse low-grade gliomas.
    Neuro Oncol. 2015;17:323-6.
    PubMed     Text format    


  316. ZACH L, Guez D, Last D, Daniels D, et al
    Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
    Neuro Oncol. 2015;17:457-65.
    PubMed     Text format     Abstract available


  317. TSUI K, Gajjar A, Li C, Srivastava D, et al
    Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.
    Neuro Oncol. 2015;17:448-56.
    PubMed     Text format     Abstract available


  318. ZHI F, Shao N, Wang R, Deng D, et al
    Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma.
    Neuro Oncol. 2015;17:383-91.
    PubMed     Text format     Abstract available


  319. VERA-BOLANOS E, Aldape K, Yuan Y, Wu J, et al
    Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
    Neuro Oncol. 2015;17:440-7.
    PubMed     Text format     Abstract available


    February 2015
  320. HAN K, Ren M, Wick W, Abrey L, et al
    Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  321. PRABHU A, Sarcar B, Miller CR, Kim SH, et al
    Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  322. SURBECK W, Herbet G, Duffau H
    Sexuality after surgery for diffuse low-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  323. VAN DEN BENT MJ, Gao Y, Kerkhof M, Kros JM, et al
    Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  324. WANG M, Dignam JJ, Won M, Curran W, et al
    Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  325. LUDWIG N, Kim YJ, Mueller SC, Backes C, et al
    Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  326. SPIEGL-KREINECKER S, Lotsch D, Ghanim B, Pirker C, et al
    Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  327. DUCHNOWSKA R, Sperinde J, Chenna A, Huang W, et al
    Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  328. MASON WP
    End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  329. LASSEN U, Chinot OL, McBain C, Mau-Sorensen M, et al
    Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  330. SCHMAINDA KM, Zhang Z, Prah M, Snyder BS, et al
    Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  331. DUREGON E, Cassenti A, Pittaro A, Ventura L, et al
    Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  332. SARKAR S, Zemp FJ, Senger D, Robbins SM, et al
    ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  333. IWAMOTO FM, Lassman AB
    Factorial clinical trials: a new approach to phase II neuro-oncology studies.
    Neuro Oncol. 2015;17:174-6.
    PubMed     Text format    


  334. ALEXANDER BM, Galanis E, Yung WK, Ballman KV, et al
    Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
    Neuro Oncol. 2015;17:180-8.
    PubMed     Text format     Abstract available


  335. PACHOW D, Wick W, Gutmann DH, Mawrin C, et al
    The mTOR signaling pathway as a treatment target for intracranial neoplasms.
    Neuro Oncol. 2015;17:189-99.
    PubMed     Text format     Abstract available


    January 2015
  336. THOMAS AA, Fisher JL, Rahme GJ, Hampton TH, et al
    Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  337. PITZ MW, Eisenhauer EA, MacNeil MV, Thiessen B, et al
    Phase II study of PX-866 in recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  338. MCKENZIE BA, Zemp FJ, Pisklakova A, Narendran A, et al
    In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  339. RAMASWAMY V, Remke M, Adamski J, Bartels U, et al
    Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  340. MORGAN LL
    The epidemiology of glioma in adults: a "state of the science" review.
    Neuro Oncol. 2015.
    PubMed     Text format    


  341. HORBINSKI C
    Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  342. SCHUSTER J, Lai RK, Recht LD, Reardon DA, et al
    A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  343. TRIPPA L, Wen PY, Parmigiani G, Berry DA, et al
    Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  344. LEE EQ, Reardon DA, Schiff D, Drappatz J, et al
    Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  345. ZOU Y, Bai HX, Wang Z, Yang L, et al
    Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format    


  346. ALMENAWER SA, Badhiwala JH, Alhazzani W, Greenspoon J, et al
    Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  347. ZINN PO, Singh SK, Colen RR
    Shedding light on glioblastoma cellular heterogeneity.
    Neuro Oncol. 2015.
    PubMed     Text format    


  348. OSTROM QT, de Blank PM, Kruchko C, Petersen CM, et al
    Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
    Neuro Oncol. 2015;16 Suppl 10:x1-x36.
    PubMed     Text format     Abstract available


  349. MCNEILL RS, Vitucci M, Wu J, Miller CR, et al
    Contemporary murine models in preclinical astrocytoma drug development.
    Neuro Oncol. 2015;17:12-28.
    PubMed     Text format     Abstract available


  350. LEE JS, Park JR, Kwon OS, Lee TH, et al
    SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.
    Neuro Oncol. 2015;17:95-106.
    PubMed     Text format     Abstract available


  351. WANG J, Pulido JS, O'Neill BP, Johnston PB, et al
    Second malignancies in patients with primary central nervous system lymphoma.
    Neuro Oncol. 2015;17:129-35.
    PubMed     Text format     Abstract available


    December 2014
  352. ZAMYKAL M, Martens T, Matschke J, Gunther HS, et al
    Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  353. HUTTERER M, Hattingen E, Palm C, Proescholdt MA, et al
    Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  354. ZHAO X, Zhao Y, Lin Q, Yu L, et al
    Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  355. CHAE M, Peterson TE, Balgeman A, Chen S, et al
    Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  356. MUNCK AF ROSENSCHOLD P, Costa J, Engelholm SA, Lundemann MJ, et al
    Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  357. KAUL A, Toonen JA, Cimino PJ, Gianino SM, et al
    Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  358. TRUFFAUX N, Philippe C, Paulsson J, Andreiuolo F, et al
    Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  359. TSELIKAS L, Souillard-Scemama R, Naggara O, Mellerio C, et al
    Imaging of gliomas at 1.5 and 3 Tesla - A comparative study.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  360. MA DJ, Galanis E, Anderson SK, Schiff D, et al
    A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  361. GUTMANN DH
    Microglia in the tumor microenvironment: taking their TOLL on glioma biology.
    Neuro Oncol. 2014.
    PubMed     Text format    


  362. FENG H, Li Y, Yin Y, Zhang W, et al
    Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived growth factor receptor alpha
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  363. TRISTER A, Scott J, Rockne R, Yagle K, et al
    Response to "Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas".
    Neuro Oncol. 2014;16:1670-1.
    PubMed     Text format    


  364. HUSE JT
    TERT promoter mutation designates biologically aggressive primary glioblastoma.
    Neuro Oncol. 2014.
    PubMed     Text format    


  365. LEHRER S, Green S, Rosenzweig KE, Rendo A, et al
    No circulating human cytomegalovirus in 14 cases of glioblastoma.
    Neuro Oncol. 2014.
    PubMed     Text format    


  366. HU F, a Dzaye OD, Hahn A, Yu Y, et al
    Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


    November 2014
  367. KILBURN LB, Kocak M, Decker RL, Wetmore C, et al
    A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  368. GUNN ME, Lahdesmaki T, Malila N, Arola M, et al
    Late morbidity in long-term survivors of childhood brain tumors: a nationwide registry-based study in Finland.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  369. STOLTZ K, Sinyuk M, Hale JS, Wu Q, et al
    Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  370. SHAH N, Schroeder B, Cobbs C
    MGMT methylation in glioblastoma: tale of the tail.
    Neuro Oncol. 2014.
    PubMed     Text format    


  371. LIU F, Scantlebury N, Tabori U, Bouffet E, et al
    White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  372. CHOI SA, Choi JW, Wang KC, Phi JH, et al
    Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


  373. MAROSI C
    Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.
    Neuro Oncol. 2014.
    PubMed     Text format    


  374. GREEN AL, Ramkissoon SH, McCauley D, Jones K, et al
    Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


    October 2014
  375. SCHIFF D, Lee EQ, Nayak L, Norden AD, et al
    Medical management of brain tumors and the sequelae of treatment.
    Neuro Oncol. 2014.
    PubMed     Text format     Abstract available


    September 2014
  376. PALLUD J, Duffau H
    Is a prospective trial necessary to suggest a clinical relevance?
    Neuro Oncol. 2014;16:1295-6.
    PubMed     Text format    


    August 2014
  377. WEN PY
    Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma?
    Neuro Oncol. 2014;16:1032.
    PubMed     Text format    


  378. DEANGELIS LM
    Whither whole brain radiotherapy for primary CNS lymphoma?
    Neuro Oncol. 2014;16:1032-4.
    PubMed     Text format    


  379. WELLER M
    The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma.
    Neuro Oncol. 2014;16:1035-6.
    PubMed     Text format    


  380. VILLANO JL, Pittman T
    Straying from the path in neuro-oncology.
    Neuro Oncol. 2014;16:1155-6.
    PubMed     Text format    


  381. MATHEW RK, O'Kane R, Parslow R, Stiller C, et al
    Comparison of survival between the UK and US after surgery for most common pediatric CNS tumors.
    Neuro Oncol. 2014;16:1137-45.
    PubMed     Text format     Abstract available


  382. ANTOSZCZYK S, Spyra M, Mautner VF, Kurtz A, et al
    Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
    Neuro Oncol. 2014;16:1057-66.
    PubMed     Text format     Abstract available


    June 2014
  383. LIU Z, Zhao X, Wang Y, Mao H, et al
    A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.
    Neuro Oncol. 2014;16:787-99.
    PubMed     Text format     Abstract available


  384. THEELER BJ, Ellezam B, Sadighi ZS, Mehta V, et al
    Adult pilocytic astrocytomas: clinical features and molecular analysis.
    Neuro Oncol. 2014;16:841-7.
    PubMed     Text format     Abstract available


    May 2014
  385. KINOSHITA M, Sasayama T, Narita Y, Yamashita F, et al
    Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis.
    Neuro Oncol. 2014;16:728-34.
    PubMed     Text format     Abstract available


  386. REYES-BOTERO G, Dehais C, Idbaih A, Martin-Duverneuil N, et al
    Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
    Neuro Oncol. 2014;16:662-70.
    PubMed     Text format     Abstract available


    April 2014
  387. LIAO B, Shroff S, Kamiya-Matsuoka C, Tummala S, et al
    Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
    Neuro Oncol. 2014;16:589-93.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: